Thermo Fisher Scientific Inc (TMO) Shares Sold by Novare Capital Management LLC

Novare Capital Management LLC decreased its position in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 1.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 36,943 shares of the medical research company’s stock after selling 685 shares during the period. Thermo Fisher Scientific makes up approximately 1.5% of Novare Capital Management LLC’s investment portfolio, making the stock its 26th biggest position. Novare Capital Management LLC’s holdings in Thermo Fisher Scientific were worth $6,445,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of TMO. Waldron LP grew its position in shares of Thermo Fisher Scientific by 48.1% during the first quarter. Waldron LP now owns 4,455 shares of the medical research company’s stock valued at $661,000 after purchasing an additional 1,447 shares in the last quarter. Security National Trust Co. grew its position in shares of Thermo Fisher Scientific by 2.6% during the first quarter. Security National Trust Co. now owns 21,183 shares of the medical research company’s stock valued at $3,254,000 after purchasing an additional 540 shares in the last quarter. Reynders McVeigh Capital Management LLC grew its position in shares of Thermo Fisher Scientific by 6.8% during the first quarter. Reynders McVeigh Capital Management LLC now owns 14,577 shares of the medical research company’s stock valued at $2,239,000 after purchasing an additional 925 shares in the last quarter. Dowling & Yahnke LLC grew its position in shares of Thermo Fisher Scientific by 4.8% during the first quarter. Dowling & Yahnke LLC now owns 10,374 shares of the medical research company’s stock valued at $1,593,000 after purchasing an additional 471 shares in the last quarter. Finally, First Bank & Trust purchased a new position in shares of Thermo Fisher Scientific during the first quarter valued at about $338,000. Hedge funds and other institutional investors own 83.52% of the company’s stock.

Thermo Fisher Scientific Inc (NYSE TMO) opened at 190.63 on Friday. The company has a 50-day moving average price of $180.21 and a 200 day moving average price of $170.53. The stock has a market cap of $74.37 billion, a price-to-earnings ratio of 33.21 and a beta of 1.05. Thermo Fisher Scientific Inc has a 52-week low of $139.07 and a 52-week high of $194.30.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, July 26th. The medical research company reported $2.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.27 by $0.03. Thermo Fisher Scientific had a net margin of 11.80% and a return on equity of 15.97%. The company had revenue of $5 billion during the quarter, compared to analysts’ expectations of $4.92 billion. During the same quarter in the prior year, the company earned $2.03 EPS. Thermo Fisher Scientific’s revenue was up 10.2% compared to the same quarter last year. On average, analysts expect that Thermo Fisher Scientific Inc will post $9.35 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, October 16th. Investors of record on Friday, September 15th will be paid a dividend of $0.15 per share. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $0.60 annualized dividend and a yield of 0.31%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.45%.

TMO has been the subject of a number of research analyst reports. Bank of America Corporation restated a “buy” rating and set a $210.00 price objective (up previously from $200.00) on shares of Thermo Fisher Scientific in a research report on Friday, July 21st. Cleveland Research upgraded Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a research report on Thursday, July 20th. Citigroup Inc. restated a “buy” rating and set a $201.00 price objective (up previously from $182.00) on shares of Thermo Fisher Scientific in a research report on Monday, July 10th. BidaskClub lowered Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, June 27th. Finally, Deutsche Bank AG set a $200.00 price objective on Thermo Fisher Scientific and gave the company a “buy” rating in a research report on Saturday, June 10th. One research analyst has rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. Thermo Fisher Scientific presently has a consensus rating of “Buy” and a consensus price target of $193.56.

In related news, Director Jim P. Manzi sold 1,000 shares of the company’s stock in a transaction dated Thursday, August 17th. The shares were sold at an average price of $175.20, for a total transaction of $175,200.00. Following the completion of the sale, the director now owns 38,757 shares of the company’s stock, valued at approximately $6,790,226.40. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director C Martin Harris sold 360 shares of the company’s stock in a transaction dated Wednesday, August 30th. The shares were sold at an average price of $180.97, for a total transaction of $65,149.20. Following the sale, the director now directly owns 5,312 shares of the company’s stock, valued at approximately $961,312.64. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 22,738 shares of company stock valued at $4,021,512. 0.49% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: “Thermo Fisher Scientific Inc (TMO) Shares Sold by Novare Capital Management LLC” was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://www.chaffeybreeze.com/2017/09/16/thermo-fisher-scientific-inc-tmo-shares-sold-by-novare-capital-management-llc.html.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply